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J uvenile differentiated thyroid carcinoma (DTC),  papillary thyroid cancer (PTC) and follicular thy-
roid cancer (FTC) are rare malignancies,  collectively 
accounting for 0.5-3% of childhood carcinomas [1].  
However,  recent data from the National Cancer Institute’s 
Surveillance,  Epidemiology,  and End Results (SEER) 
program have shown that the incidence of thyroid can-
cer in childhood is increasing [2 , 3].  DTC in children is,  
in many ways,  a disease distinct from DTC in adults 
[4-8].  Although children most often present with 
extensive and aggressive disease and have a higher fre-
quency of recurrence,  their prognosis is excellent,  with 
a low mortality rate even when advanced disease is 
present.
Recently,  the American Thyroid Association (ATA),  
recognizing these differences,  released 2 separate 
guidelines for thyroid nodules and DTC specific to chil-
dren and adults [9 , 10].  The current recommendation 
for the initial management of these young patients is 
total thyroidectomy followed by radioactive iodine 
(RAI),  if the patient is a good candidate,  and levothy-
roxine suppressive therapy [4 , 5 , 9].  Several prognostic 
factors have been well established and are currently 
cited in the ATA Adult DTC Guidelines: extremes of 
age,  relatively large tumors,  multicentricity,  extrathy-
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Differentiated thyroid carcinoma (DTC) in juvenile patients is often an extensive and aggressive disease with a 
high frequency of recurrence.  However,  the prognosis is excellent,  with a low mortality rate even when 
advanced disease is present,  although prognostic factors and treatment strategy remain uncertain.  Between 
April 2004 and March 2017,  33 juvenile patients (< 30 years old) were diagnosed with DTC and treated at our 
institution.  We retrospectively investigated prognosis and factors including sex,  reason for discovery,  treat-
ment,  pathological factors and treatment progress to clarify the risk factors.  All patients underwent curative 
surgical treatment.  Pathologically,  lymph node metastasis was identified in 25 patients (75%).  Thirteen 
patients (39%) had bilateral cervical metastasis.  In addition,  9 (27%) had more than 10 metastatic lymph 
nodes.  The 2 patients with more than 20 metastatic lymph nodes were treated with radioactive iodine (RAI).  
Five patients (15%) had local recurrences and received surgery.  There have been no further recurrences or 
deaths.  However,  no factors were determined to significantly predict the recurrence of juvenile DTC.  Local 
recurrent disease was treated with surgery and/or RAI until remission,  and survival was excellent in juvenile 
DTC.
Key words:  differentiated thyroid carcinoma,  juvenile,  children
Received January 27, 2020 ; accepted May 13, 2020.
＊Corresponding author. Phone : +81-86-235-7265; Fax : +81-86-235-7269
E-mail : tshien@md.okayama-u.ac.jp (T. Shien)
Conflict of Interest Disclosures: No potential conflict of interest relevant 
to this article was reported.
roidal extension (Ex),  lymph node metastasis,  vascular 
invasion,  and elevated postoperative thyroglobulin 
[10].  In contrast,  conflicting results related to these 
prognostic factors have been reported in juvenile cases 
[11-13].  Local cancer relapse is more frequent in juve-
niles than in adults.  Recurrence in cervical lymph 
nodes requires surgical intervention,  with the potential 
risk of postoperative complications.  Despite the high 
recurrence rate,  juvenile DTC generally has an excellent 
outcome and overall prognosis [14-17].  This study 
aimed to retrospectively analyze the probability of 
recurrence,  prognostic factors,  treatments,  and out-
comes of juvenile DTC.
Patients and Methods
We defined patients under age 30 years as having 
juvenile onset.  Between April 2004 and March 2017,  
33 juvenile patients were diagnosed with DTC and treated 
at the Okayama University Hospital.  We retrospectively 
investigated clinical and pathological factors,  operative 
methods,  factors related to recurrence,  postoperative 
treatment plans,  and treatment progress.  This study 
was approved by the Ethics Committee of Okayama 
University Hospital (No.1907-010) and adhered to the 
Declaration of Helsinki.
Treatment. We tailor our DTC surgical strategies 
to individual patients,  as described below.  We consider 
total thyroidectomy to carry a risk of serious complica-
tions,  especially in juveniles,  such as recurrent nerve 
paralysis,  postoperative bleeding,  hypothyroidism,  
hypocalcemia,  and so on.  We usually select hemithy-
roidectomy unless gland metastasis and/or cervical 
lymph node metastasis is present,  in which case RAI 
treatment is indicated.  In addition,  all patients who 
received total thyroidectomy and/or RAI were also 
treated with L-thyroxine at suppressive doses.  We do 
not alter our DTC treatment policy according to age.
Ipsilateral modified neck dissection was performed 
for patients with > 1 cm tumor size,  extrathyroidal 
extension and lymph node metastases.  We preopera-
tively diagnosed lymph node metastasis using ultra-
sound (US) or positron emission tomography/com-
puted tomography (PET/CT).  If it was difficult to 
diagnose the metastases,  we performed fine-needle 
aspiration biopsy.
Statistical analysis. This was a non-planned,  ret-
rospective,  exploratory project.  All available cases were 
studied without a predefined sample size calculation to 
detect a specific effect size or reach a certain level of 
power.  We used Cox proportional hazard model analy-
sis to identify factors potentially related to recurrences.  
Data were analyzed with EZR (version 1.37).  P values of 
< 0.05 were considered to indicate a statistically signifi-
cant difference [18].
Results
Patient characteristics and preoperative diagnosis.
Patient characteristics are presented in Table 1.  The 
median age was 25 (11-30) years.  Six patients (18%) 
were male and 27 female (82%); the male/female ratio 
was 1 : 4.5.  The median follow-up period was 61 months 
(4-122).  The reasons for detection of malignancy were 
as follows: examination at a school or company work-
place in 10 cases (30%); self-detection of a neck lump 
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Table 1　 Clinicopathological characteristics and preoperative 
diagnosis of juvenile DTC patients (n=33)
Characteristics N=33
Sex
Male  6 (18%)
Female 27 (82%)
Age (median year) 25 (11-30)
Observation period (median month) 61 (4-122)
Discovery motive
Neck lump  7 (21%)
Pointed out by friends  2 (6%)
Examination by school or company 10 (30%)
Follow-up of other thyroid disorder  2 (6%)
Hospital consultation with a cold  5 (15%)
found by CT inspection with other diseases  7 (21%)
Tumor location
Unilaterality 29 (88%)
Right lobe 18 (54%)
Left lobe 11 (33%)
Bilaterality  4 (12%)
Tumor size (median mm) 23 mm
T1 15 (45%)
T2 14 (42%)
T3  4 (12%)
Lymph node metastasis
N0 22 (66%)
N1a  3 (9%)
N1b  8 (24%)
in 7 (21%); detection during CT for other diseases in 7 
(21%); notification by friends in 2 (6%); and follow-up 
for other thyroid disorders in 2 (6%).  
The tumor locations were unilateral in 29 cases 
(88%) and bilateral in 4 (12%).  The median clinical 
tumor size was 23 mm (9-60: cT1 was confirmed in 
15 cases (45%),  cT2 in 14 (42%) and cT3 in 4 (12%)).  
Eleven patients (33%) were judged to have lymph node 
metastasis by US or PET/CT.  Three (9%) had N1a and 
8 (24%) had N1b disease.  No patients had distant 
metastasis.  Regarding TNM staging,  all patients were 
classified as stage I.
Treatment. Surgical treatments are listed in Table 2.  
Seven patients (21%) underwent total thyroidectomy,  4 
(12%) because they had thyroid cancer beyond glandu-
lar metastasis.  All 7 patients had lymph node metasta-
sis.  The dissection range was ipsilateral cervical dissec-
tion in 27 cases (81%) and bilateral cervical dissection 
(BCLN) in 5 (15%).  We added RAI to the treatment 
regimen for 2 patients because both had over 20 meta-
static lymph nodes and Ex.
Pathological diagnosis. The pathological diagnoses 
are listed in Table 2.  Thirty-one patients (91%) had PTC,  
1 (3%) had FTC,  and 1 (3%) had widely invasive FTC.  
The median tumor size was 26 mm (7-70).  Sixteen cases 
(48%) had Ex.  Regarding pT staging,  11 patients (33%) 
had pT1,  6 (16%) pT2,  14 (42%) pT3,  1 (3%) pT4a,  
and 1 (3%) pT4b.  
Cervical lymph node metastasis was identified in 
25 patients (75%).  Thirteen patients (39%) had bilateral 
cervical metastasis.  In addition,  9 (27%) had more than 
10 metastatic lymph nodes.
Prognosis. During a median follow-up of 61 months,  
28 patients (84%) remained disease free and 5 (15%) had 
local recurrences.  The characteristics of patients who had 
recurrent disease,  including treatments and progress,  
are presented in Table 3.  Three patients (9%) under-
went surgical removal of metastatic lymph nodes; one 
was treated with BCLN,  and one with total thyroidec-
tomy + BCLN.  These patients tended to have numerous 
metastatic lymph nodes.  Postoperatively,  we did not 
administer RAI,  due to concerns about adverse effects 
on fertility.  There have been no further recurrences or 
deaths in these patients.  The risk factors related to 
recurrence were analyzed by Cox proportional hazard 
model analysis (Table 4).  The hazard ratios were 0.9 for 
age,  1.98 for sex,  1.02 for tumor size,  0.61 for Ex,  and 
0.95 for the number of lymph nodes.  However,  none of 
these factors reached statistical significance.
Discussion
In recognition of the age-related differences in DTC,  
The American Thyroid Association released two sepa-
rate guidelines for thyroid nodules and DTC specific to 
children and adults [9 , 10].  The current recommenda-
tion for the initial management of young patients is total 
thyroidectomy followed by RAI,  based on suitable indi-
cations,  and levothyroxine suppressive therapy [4 , 5 , 9].
In previous reports,  juvenile DTC was usually 
extensive and aggressive with a higher frequency of 
recurrence than other thyroid tumors.  The prognosis is 
excellent,  however,  with a low mortality rate,  even 
when advanced disease is present.  Our research yielded 
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Table 2　 Postoperative pathological diagnosis including the exis-
tence of extrathyroid extension and lymph node metastasis.
Operation of thyroid
Hemithyroidectomy 26 (78%)
Total thyroidectomy  7 (21%)
Cervical lymph node dissection
D1  5 (15%)
D2 22 (66%)
D3  5 (15%)
Pathological diagnosis
Papillary carcinoma 31 (91%)
Follicular carcinoma  1 (3%)
Follicular carcinoma,  widely invasive  1 (3%)
Tumor diameter (median mm) 26 mm
T1 11 (33%)
T2  6 (18%)
T3 14 (42%)
T4a  1 (3%)
T4b  1 (3%)
Extra-thyroid extension
Ex 0 17 (51%)
Ex 1 16 (48%)
Lymph node metastasis
N0  8 (24%)
N1a 12 (36%)
N1b 13 (39%)
Number of node metastasis
1～4  8 (24%)
5～9  8 (24%)
≧10  9 (27%)
the same results.  Ex,  more than 10 metastatic lymph 
nodes,  and cervical lymph node metastasis were found 
in 48%,  27% and 75% of our cases,  respectively.  None 
had remote recurrence.  
On the other hand,  the results for recurrence factors 
have differed among studies.  Mihailovic et al.  evaluated 
potential prognostic factors in patients who were rela-
tively young at diagnosis,  and found that less aggressive 
initial treatment and tumor multifocality were associ-
ated with recurrence.  They also found no associations 
between recurrence and either sex or metastasis,  
whether distant or involving lymph nodes [11].  
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Table 4　 The hazard ratios of risk factors by Cox proportional hazard model analysis
Risk factor Hazard rate 95% CI p value
Sex (male/female) 1.98 (0.18-21.5) 0.58
Age (year) 0.9 (0.74-1.09) 0.28
Tumor size (mm) 1.02 (0.9-1.15) 0.78
Tumor location (unilaterality/bilaterality) 0.64 (0.07-5.84) 0.7
The number of metastatic lymph nodes 0.95 (0.8-1.13) 0.57
Over 10 metastatic lymph nodes (10</≦10) 0.74 (0.13-4.16) 0.73
Extrathyroidal extension 0.61 (0.12-3.05) 0.55
Operation (partial/total thyroidectomy) 0.22 (0.02-2) 0.18
Table 3　 Characteristics,  pathological factors,  treatments and outcomes of 5 patients with local recurrences
Sex Year of diagnosis
Tumor 
location
Surgical 
treatment
Tumor size 
(mm) Ex
Number of 
metastatic 
lymph 
node(s)
Period 
until 
local 
recurrence 
(months)
Treatment 
for 
recurrence
Disease free 
period after 
treatment of 
local 
recurrence 
(months)
1 M 11 R
Hemi-
thyroidectomy 
+BCLN
13 + 14   3
Surgical 
removal of 
metastatic 
lymph node
 67+
2 F 23 L
Hemi-
thyroidectomy 
+CLND
21 +  7  24
Surgical 
removal of 
metastatic 
lymph node
 43+
3 F 25 R
Hemi-
thyroidectomy 
+BCLN
18 -  7  72
Surgical 
removal of 
metastatic 
lymph node
 72+
4 M 29 R
Total 
thyroidectomy
+BCLN
exited
gland
metastasis
(right 40,  
left 15)
+ 20 120 BCLN 122+
5 F 30 R
Hemi-
thyroidectomy 
+BCLN
34 + 14  24
Total 
thyroid-
ectomy 
+BCLN
109+
※M: male,  F: female,  R: right,  L: left
Demidchik et al.  studied 740 children and found that 
age and multifocality strongly affected recurrent nodal 
disease [19].  Enomoto et al.  studied 142 pediatric 
patients with DTC,  with a median follow-up of 22 years,  
and reported that age (< 16 years),  a familial history of 
thyroid cancer,  tumor size,  large lymph node metasta-
ses,  and Ex were risk factors for recurrent disease [20].  
Conversely,  Vaisman et al.  reported that the only two 
factors associated with recurrent disease were lymph 
node metastasis and distant metastasis.  In his cohort,  
age,  sex,  tumor size,  and multicentricity did not predict 
the success of initial therapy [12].
As may be seen from these reports,  prognostic and 
recurrent factors remain to be clarified.  There may be 
differences in the causes of DTC.  Demidchik’s report is 
from Belarus,  which was strongly influenced by 
Chernobyl,  so we consider it might be characteristic of 
DTC affected by radiation.  Moreover,  the definitions of 
young age differ among studies and are difficult to 
determine in the context of DTC.  Enomoto’s report 
considers children < 20 years old,  and the median fol-
low-up term is over 20 years.  We consider the results of 
this report to be of great value due to the long follow-up 
period.  In our study,  the median age was 25 years and 
26 patients (79%) were over 20 years old.  If we could 
have followed them for a longer time or increased the 
number of cases,  we might have obtained better results.
Other reports have shown that the extent of initial 
surgical treatment is a factor predicting recurrence.  
Some studies have revealed total thyroidectomy to be 
associated with better recurrence-free survival [21 , 22].  
Nevertheless,  others found no relationship between the 
extent of surgery and the recurrence rate [14 , 23].  
Recurrence risk might be related to RAI treatment.  
Chow et al.  reported that RAI reduced the risk of both 
locoregional and distant recurrences.  They detected 
neither secondary malignancy nor impairment of fertil-
ity in patients undergoing RAI,  and there were no 
impacts on pregnancy outcomes [24].  
No risk factors in our analysis were clearly associ-
ated with either recurrence or overall survival,  at least 
in the short term.  Furthermore,  no distant metastases 
were detected in our patients.  Previous reports on dis-
tant metastasis noted different rates,  some as low as 
2.3%,  with most being in the 6-25% range [2 , 8 , 15 , 17 ,  
19 , 22 , 25].
Overall,  thyroid cancer in juveniles has an excellent 
prognosis,  with 97-99% survival at 10 years,  and 
90-95% survival at 20 years [14 , 19 , 22 , 25].  Hogan et al.  
reported 90% survival at 30 years,  and Hay et al.  
described a 98% survival rate at 30-50 years after sur-
gery [2 , 17].
There were some limitations to this research.  First,  
our study was a retrospective observational study,  so 
the number of patients was small and the follow-up 
period short.  Second,  juvenile persons often move for 
school or work,  so follow-up at the same hospital is 
difficult.  Third,  we were not actively conducting thy-
roid ultra-sound screening for juveniles,  and the motive 
for discovery was often accidental.
Further study with a larger number of juvenile 
patients and longer observation period is needed.
In conclusion,  juvenile thyroid cancer tends to be 
more highly associated with lymph node metastasis and 
extrathyroidal invasion than adult thyroid cancer.  Local 
recurrent disease has been treated with surgery and/or 
RAI until remission and the survival rate is excellent.  
Further consideration is warranted to determine the 
optimal treatment strategy,  including surgical proce-
dures and radiation and their risk factors.
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